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ABSTRACT
 
Aims
 
To identify early onset cannabis users by measuring basal hypothalamic–pituitary–adrenal (HPA) axis activity,
which may be a risk factor for early onset substance use when showing low activity. 
 
Design
 
In a prospective cohort
study, adolescents who initiated cannabis use at an early age (9–12 years), those who initiated at a later age (13–
14 years) and those who did not use cannabis by the age of  14 were compared with respect to HPA axis activity.
 
Setting and participants
 
Data were used from the first and second assessment wave of  the TRacking Adolescents’
Individual Lives Survey (TRAILS), that included 1768 Dutch young adolescents aged 10–12 years who were followed-
up across a period of  2 years. 
 
Measurements
 
Cortisol was measured in saliva samples at awakening, 30 minutes
later and at 8 p.m. at age 10–12. Self-reported age at first cannabis use was used. 
 
Findings
 
The early onset group
had lower cortisol levels 30 minutes after awakening than the late onset group (OR 
 
=
 
 0.93, 95% CI: 0.86–0.99). Fur-
thermore, compared to non-users, the early and late onset cannabis users had higher levels of  cortisol at 8 p.m.
(OR 
 
=
 
 1.25, 95% CI: 1.03–1.53 and OR 
 
=
 
 1.21, 95% CI: 1.01–1.45, respectively). 
 
Conclusions
 
Some evidence was
found for HPA axis hypo-activity at awakening in adolescents with early onset of  cannabis use compared to late onset
users, which might indicate an increased risk for early onset users of  seeking stimulation to restore arousal levels by
using substances.
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INTRODUCTION
 
Adolescents who initiate cannabis use at an early age
have been found to be at increased risk for later depen-
dence [1,2], later psychosis [3], neuropsychological defi-
cits [4] and a variety of  other adverse health outcomes
(e.g. [5]). In particular, adolescents who initiate cannabis
use before the age of  13 may be at risk [6–8]. It is there-
fore important to be able to identify this high-risk group
among adolescents. The search for markers that predict
substance use has led many researchers to examine tem-
perament and personality factors, such as sensation-
seeking (e.g. [9]). Sensation-seeking is often defined as
‘the need for varied, novel and complex sensations and
experiences, and the willingness to take physical and
social risks for the sake of  these experiences’ [10]. These
aspects of  behaviour are associated with the activation of
the hypothalamic–pituitary–adrenal (HPA) axis, which is
a central component of  the body’s neuroendocrine
response to stress. Its major end-product cortisol has pro-
found effects on mood and behaviour. HPA axis activity
may reflect a risk factor that explains part of  the associa-
tion between temperament, personality factors and early
onset of  substance use.
Several animal studies have focused on the relation-
ship between HPA axis activity and self-administration
of  drugs. It has been found, for instance, that lower HPA
axis activity was associated with heightened acquisi-
tion of  drug self-administration in rats [11]. These find-
ings from animal studies suggest that individuals with
low responsiveness to stress may, in fact, use drugs
actively to increase the arousal effects, and evoke
stronger sensations that are essential for physiological
comfort [12].
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Animal studies have also shown that administration
of  tetrahydrocannabinol (THC), the main active com-
pound of  cannabis, enhanced the HPA axis response to a
painful stimulus and increased basal concentrations of
HPA axis hormones, such as adrenocorticotrophin hor-
mone (ACTH) and corticosterone [13,14]. Thus, using
cannabis may indeed enhance HPA axis activity.
Only few studies exist in which human HPA axis activ-
ity has been related to risk of  substance use. A study of  a
small sample of  boys whose fathers had a substance use
disorder showed that the cortisol reactivity of  these boys,
who may be regarded as being at high risk of  developing a
substance use disorder, was lower when anticipating a
stress task when compared to normal controls [15]. Sim-
ilar results were found in a larger sample of  high-risk
boys, who also had a substance-abusing father [16]. To
our knowledge, there have been no studies that have
examined the prospective relationship between HPA axis
activity and onset of  cannabis use.
To study HPA axis dysregulation as a risk factor con-
tributing to the onset of  substance use, longitudinal data
are needed covering a period in which adolescents start to
experiment with substance use. Salivary cortisol is now
used commonly as an index of  HPA axis activity, because
it is non-invasive and comparatively inexpensive to col-
lect and analyse [17]. Cortisol concentrations follow a
circadian rhythm [18]. Cortisol levels start to rise after
awakening, peak at about half  an hour after awakening
[19,20] and decrease during the day.
Other aspects that should be taken into account when
studying cortisol levels are gender and pubertal develop-
ment. There is some evidence for gender differences in
basal levels of  cortisol. Klimes-Dougan 
 
et al
 
. [21] reported
higher salivary cortisol levels in female than in male con-
trols at mid-day and late afternoon. Gonadal steroids are
known to interact with the HPA axis, and oestrogens in
particular have been shown to stimulate HPA axis
activity [22–24]. Thus, when studying the relationship
between HPA axis activity and substance use onset,
pubertal stage should also be taken into account.
The present study examined whether adolescents who
initiated cannabis use before the age of  13 (9–12 years),
those who initiated cannabis use at a later age (13–
14 years) and those who did not use any substance by the
age of  14 differed with respect to HPA axis activity. We
hypothesized that hypo-activity of  the HPA axis is related
to an increased risk of  early onset cannabis use.
 
METHODS
 
Participants
 
The TRacking Adolescents’ Individual Lives Survey
(TRAILS) is a prospective cohort study of  Dutch early
adolescents aged 10–12 years, who were followed-up
across a period of  2 years and who will have several fol-
low-up measurements in the future. Data collection at
the first and second assessment waves took place from
March 2001 to July 2002, and from September 2003 to
May 2004, respectively. The TRAILS target sample com-
prised young adolescents from five municipalities in the
north of  the Netherlands, including both urban and rural
areas [25]. The average age at the first assessment was
11.1 years and at the second assessment was 13.6 years.
The sample selection involved two steps. First, the
municipalities were requested to provide names and
addresses of  all inhabitants born between 10 January
1989 and 30 September 1990 (first two municipalities)
or between 10 January 1990 and 30 September 1991
(last three municipalities), which yielded 3483 names.
Simultaneously, primary schools (including schools for
special education) within these municipalities were
approached with a request to participate. School partici-
pation was a prerequisite for eligible adolescents and
their parents to be approached by TRAILS, with the
exception of  adolescents who already attended secondary
schools (
 
<
 
 1%), who were contacted without involving
their schools. Of  the 135 primary schools within the
municipalities, 122 (90.4%) schools agreed to partici-
pate, accommodating 90.3% of  the adolescents. Sec-
ondly, if  schools agreed to participate, parents (or
guardians) received two brochures, one for themselves
and one for their adolescents, with information about the
study. In addition, a TRAILS staff  member visited the
schools to inform eligible adolescents about the study.
More details about the procedure have been published
elsewhere [25].
The exclusion criteria were: (1) adolescent incapable
of  participating because of  intellectual disability or a
serious physical illness or handicap; (2) Dutch-speaking
parent or parent surrogate not available, and not feasible
to administer a part of  the measurements in parent’s own
language. Of  all subjects who were approached
(
 
n
 
 
 
=
 
 3145), 6.7% were excluded. Of  the remaining 2935
young adolescents, 76.0% were included in the study
(
 
n
 
 
 
=
 
 2230, mean age 11.09 years, SD 0.55, 50.8%
female). A high response rate (96%) was yielded at the
second assessment. Saliva samples were received at the
first assessment wave of  1768 children (79.3% of  all
TRAILS participants).
 
Procedure
 
At the first assessment, well-trained interviewers visited
one of  the parents or guardians in their homes to admin-
ister an interview covering a wide range of  topics. In addi-
tion, the parent was asked to complete a questionnaire.
Children were measured at school, where they completed
questionnaires in groups under the supervision of  one or
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more TRAILS assistants. In addition, information-pro-
cessing capabilities (neurocognitive tasks), intelligence
and a number of  biological parameters (including weight
and height) were assessed individually at school. Saliva
samples were collected at home using the Salivette sam-
pling device (Sarstedt, Nümbrecht, Germany), which was
given to the parent at the parent interview, accompanied
by verbal and written instructions. Teachers completed a
brief  questionnaire for each TRAILS child in their class.
The second assessment involved only self-report ques-
tionnaires, to be completed by the children (or young
adolescents), their parents and their teachers. The ado-
lescents completed their questionnaires at school, super-
vised by TRAILS assistants.
 
Measures
 
Cannabis use
 
Cannabis use by the participant was measured at the first
and second assessments by four self-report items. The first
question concerned the age of  first cannabis use, with the
following answer categories: never used, 9 years or
younger, 10, 11, 12, 13 or 14 years). Children were also
asked about life-time use, use in the last year and use in
the last month with the following questions: ‘How often
have you used cannabis in your life/in the last year/in the
last months’, with answer categories: ‘I have never used’,
‘used it once’, ‘used it twice’, ‘three times’, . . . , ‘10
times’, ‘11–19 times’, ‘20–39’ times, ‘40 times or more’).
For the present study we used the age at first use and
formed three groups: (1) early onset, i.e. age at first use
was 9–12 years, (2) later onset, i.e. age at first use was
13–14 years and (3) non-users, i.e. adolescents who had
not experimented with cannabis use by the age of  14 at
the second assessment.
 
Cortisol
 
Collection of  salivary cortisol is a relatively stress-free
approach that avoids confounding by stress responses,
e.g. as induced by venipuncture, and correlations
between saliva cortisol levels and serum cortisol concen-
trations are high [26]. Cortisol concentrations in the col-
lected samples depend strongly on the time of  the day that
samples are taken. For the present study we focused on
cortisol measures taken by means of  Salivettes shortly
after awakening, still lying in bed (cortisol 1), 30 minutes
after awakening (cortisol 2) and at 8 p.m. (cortisol 3) to
cover various time-points during the circadian rhythm
that have been found to be relevant [27]. TRAILS partic-
ipants collected their saliva at home, using the Salivette
sampling device (Sarstedt, Rommelsdorfer Str, D-51588
Nümbrecht, Germany), which was given to the parent at
the parent interview, accompanied by verbal and written
instructions. The Salivette tube consists of  a plastic
sampling vessel with a suspended insert containing a
sterile neutral cotton wool swab that has to be chewed for
about 45 seconds and then returned to the insert. A
recent study by Shirtcliff  
 
et al
 
. [41] showed that results for
salivary cortisol were not affected by the use of  Salivettes.
Both the sampling and the preceding day should be nor-
mal (school) days, without special events or stressful cir-
cumstances. Because the schools participating in TRAILS
started at approximately the same time, the sampling-
time variation of  the morning samples among the chil-
dren is limited and the estimated corresponding times are
07.00 hours for the first sample (group 1) and
07.30 hours for the second sample (group 2). Children
were instructed not to collect saliva when they were ill,
had a cold, had a headache or were menstruating. Fur-
thermore, they were requested not to take any medica-
tion, if  possible. Any deviations from this protocol, either
in terms of  sampling times or in terms of  other require-
ments, were indicated on an accompanying form. Con-
cerning the sampling procedure itself, subjects were
instructed to keep a glass of  water next to their bed and to
rinse their mouth thoroughly with tap water before sam-
pling saliva, and not to consume sour products or brush
their teeth shortly beforehand. Saliva samples were
stored by the participants in their freezer directly after
sampling and mailed to the institute as soon as possible
(but not on Fridays and Saturdays, in order to prevent
unnecessary delay due to the weekend). The saliva sam-
ples were stored at 
 
−
 
20
 
°
 
C until analysis. Previous studies
suggest that salivary cortisol levels are stable for pro-
longed periods of  time at 
 
−
 
20
 
°
 
C [28]. Participants who
did not return the Salivettes within 2 months were sent a
reminder letter [29].
A time-resolved fluorescence immunoassay was used
in order to determine the cortisol concentration in the
saliva samples. After thawing, saliva samples were cen-
trifuged at 2000 
 
g
 
 for 10 minutes, which resulted in a
clear supernatant of  low viscosity; 100 ml of  saliva were
used for duplicate analysis. Cortisol levels were deter-
mined employing a competitive solid-phase time-resolved
fluorescence immunoassay with fluorometric end-point
detection (DELFIA 
 
=
 
 dissociation-enhanced lanthanide
fluorescent immunoassays). Ninety-six-well Maxisorb
microtitre plates (Nunc, Wiesbaden, Germany) were
coated with rabbit–anti-ovine immunoglobulin. After an
incubation period of  48 hours at 4
 
°
 
C plates were washed
three times with washbuffer (pH 
 
=
 
 7.4, containing
sodium phosphate and Tween-40). In the next step the
plates were coated with an ovine anti-cortisol antibody
and incubated for 48 hours at 4
 
°
 
C. Synthetic saliva
mixed with cortisol in a range from 0 to 100 nmol/l
served as standards. Standards, controls (saliva pools)
and samples were given in duplicate wells. Fifty microli-
tres of  biotin-conjugated cortisol was added and after
 © 2006 The Authors. Journal compilation © 2006 Society for the Study of  Addiction
 
Addiction, 
 
101
 
, 1581–1588
 
1584
 
Anja C. Huizink 
 
et al.
30 minutes of  incubation the non-binding cortisol/
biotin-conjugated cortisol was removed by washing
(three times). Two hundred microlitres of  europium–
streptavidin (Wallac Oy, Turku, Finland) was added to
each well and after 30 minutes and six washings 200 
 
µ
 
l
enhancement solution was added (Pharmacia, Freiburg,
Germany). Within 15 minutes on a shaker the enhance-
ment solution induced fluorescence, which can be
detected with a DELFIA fluorometer (Wallac). A standard
curve was generated and the cortisol concentration of  the
samples was calculated with a computer-controlled
program. The intra-assay coefficient of  variation was
between 4.0 and 6.7%, and the corresponding interassay
coefficients of  variation were between 7.1 and 9.0% [29].
Cortisol was assessed in 1768 children. We excluded
22 children because of  the use of  corticosteroid-contain-
ing medication. We next analysed the effect of  other
remarks concerning the sampling procedure that parents
indicated on the accompanying form (such as stressful
events during the day or deviations in terms of  sampling
times), and found no further reasons for exclusion. For
each time-point, cortisol values that were above 3 stan-
dard deviations (SD) of  the mean were excluded from the
analysis in order to reduce the impact of  outliers (cortisol
1, 21 excluded; cortisol 2, 11 excluded; cortisol 3, 18
excluded). After this exclusion, cortisol levels followed a
normal distribution.
 
Pubertal stage
 
Pubertal stage was assessed using schematic drawings of
secondary sex characteristics associated with the five
Tanner stages of  pubertal development [30], a method
that is used widely and has demonstrated good reliability
and validity [31,32]. Stage of  pubertal development was
assessed in the parent interview using schematic draw-
ings of  secondary sex characteristics associated with the
five standard Tanner stages of  pubertal development [33].
Tanner stages are a widely accepted standard for assess-
ment of  physical development, and have demonstrated
good reliability, validity and parent–child agreement
[32,33]. A parent (usually the mother) was provided
with gender-appropriate sketches, and asked to select
which of  the sketches ‘looked most like the child’. Based
on parent ratings, children were classified into five stages
of  puberty, in which stage 1 corresponds to infantile and
stage 5 to complete puberty [34].
 
Statistical analyses
 
We checked whether non-responders differed from
responders on various background characteristics by
means of  
 
χ
 
2
 
 and 
 
t
 
-tests. Descriptives for prevalence of  can-
nabis use and age at onset and for the different cortisol
measures (cortisol 1, cortisol 2 and cortisol 3) were com-
puted. Next, three multivariate logistic regression analy-
ses were conducted with age of  onset of  cannabis use
(early onset versus no use; later onset versus no use; early
versus later onset) as dependent variable, and cortisol 1,
cortisol 2 and cortisol 3 as multivariate predictors in each
model. All analyses were adjusted for gender and Tanner
stage by including them as covariates in the regression
models. Odds ratios (ORs) and their 95% confidence
intervals (CI) were estimated. The analyses were carried
out using SPSS version 12.0, and 
 
P
 
 
 
<
 
 0.05 (two-tailed)
was used to determine statistical significance.
 
RESULTS
 
Non-responders analysis
 
Responders and non-responders did not differ with
respect to the proportion of  single-parent families or the
prevalence of  teacher-rated problem behaviour. Further-
more, no differences between responders and non-
responders were found regarding associations between
socio-demographic variables and mental health out-
comes [25]. Non-responders did not differ from respond-
ers in terms of  gender [in the non-responders group
48.48% were male compared to 49.43% male in the
responders group, 
 
χ
 
2
 
( df  
 
=
 
 1) 
 
=
 
 0.13; 
 
P
 
 
 
=
 
 0.72] or puber-
tal development (average Tanner score 
 
=
 
 1.92 versus
1.86, 
 
t
 
 
 
=
 
 
 
−
 
1.39; 
 
P
 
 
 
=
 
 0.16), but non-responders were
slightly  older  (11.16 years  versus  11.08 years,  
 
t
 
 
 
=
−
 
3.08; 
 
P
 
 
 
=
 
 0.002).
 
Descriptives
 
Descriptive information regarding the prevalence of  can-
nabis use and the age at onset of  cannabis use for cortisol
1, cortisol 2 and cortisol 3 is presented in Table 1 for all
participants (
 
n
 
 
 
=
 
 1441) who had complete data on all
variables included in the analyses. The cortisol samples
were only modestly intercorrelated (
 
r
 
s ranging from 0.17
to 0.26, 
 
P
 
s 
 
<
 
 0.005), which indicates that multi-col-
linearity is most probably not at stake. Background char-
acteristics of  the three analytical groups are presented in
Table 2.
 
Logistic regression analyses
 
Results of  the logistic regression analyses are presented in
Table 3. For one early starter and two late starters we had
missing data on pubertal stage, and therefore these par-
ticipants were excluded from the logistic regression anal-
yses. The results show that both early and later onset of
cannabis use were associated with an increased risk of
higher cortisol levels at 8 p.m. when compared to non-
users (OR 
 
=
 
 1.25, 95% CI 
 
=
 
 1.03–1.53 and OR 
 
=
 
 1.21,
95% CI 
 
=
 
 1.01–1.45, respectively). When early and later
starters of  cannabis use were compared, the early onset
group had statistically significant lower cortisol levels
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30 minutes after awakening (OR 
 
=
 
 0.93, 95% CI 
 
=
 
 0.86–
0.99).
 
DISCUSSION
 
Various studies have shown that substance use before the
age of  13 years predicts substance abuse problems at later
ages [6–8]. It is therefore of  importance to obtain a better
understanding of  the processes that act to promote early
use. The present study was the first that examined pro-
spectively whether HPA axis basal activity predicts early
onset cannabis use. Interestingly, early onset and later
onset of  cannabis use could be differentiated by means of
cortisol levels 30 minutes after awakening. Early onset of
cannabis use was related to lower levels of  cortisol at this
time of  day, when compared to adolescents with later
onset. Thus, adolescents with early onset of  cannabis use
had a slightly blunted cortisol awakening response that
was different from non-users and, in particular, from
adolescents with a later onset of  cannabis use. Further-
more, our results showed a trend towards a significant
association between low cortisol levels 30 minutes after
awakening and early onset cannabis use compared to
non-users. However, statistically significant associations
were found between higher, instead of  lower, cortisol lev-
els at 8 p.m. and either early onset or later onset of  can-
nabis use, compared to non-users. In the evening, the
expected decrease in cortisol levels due to its circadian
rhythm was most profound for non-users, whereas both
early and later onset of  cannabis use were related to
higher cortisol levels.
The awakening response of  cortisol is regarded as a
marker of  basal cortisol physiology, and has recently
received considerable attention (see [27] for a review).
This cortisol awakening response has been shown to be
an intraindividually stable phenomenon. For instance,
Clow 
 
et al
 
. [27] found an intracorrelation of  
 
r
 
 
 
=
 
 0.71 for
the awakening response over 2 consecutive days. More-
over, this awakening response seems able to reveal subtle
interindividual changes in HPA regulation [35], appear-
ing to be under a different regulatory influence than the
remaining diurnal profile. For example, the cortisol
awakening response is under genetic influences, which
explain 40–59% of  the variance [20,36], whereas
evening levels of  cortisol are mainly to due environmen-
tal influences [20,36]. Thus, adolescents with early onset
of  cannabis use may have a different genetic constellation
than adolescents with a later onset of  cannabis use,
which may relate to their blunted cortisol awakening
response. In line with the stimulation-seeking theory
[10], their lower arousal in the morning may put them at
risk of  seeking stimulation, perhaps by using substances
in order to restore their arousal levels to an optimal or
normal level.
Various studies have shown that temperament and
personality factors, such as sensation-seeking (e.g.
[9,37]), are related to early onset of  cannabis use. The
relation between cortisol and sensation-seeking behav-
iour has also been tested and most studies report an
inverse association, with lower cortisol levels for (mostly
male) individuals with high sensation-seeking levels [38–
40]. Thus, hypo-activity of  the HPA axis under basal
conditions may be a risk factor that explains part of  the
relationship between some aspects of  temperament and
personality and early onset of  substance use. Hypo-
activity of  the HPA axis has also been reported for boys
with higher levels of  externalizing problem behaviours
in normal, at-risk and psychiatric groups [41].
 
Table 1
 
Descriptives of  cortisol and prevalence and age of  onset of  cannabis use.
 
Mean SD Range
 
Cortisol 1 nmol/l 11.53 (
 
n
 
 
 
=
 
 1441) 4.67 0.71–29.42
Cortisol 2 nmol/l 15.26 (
 
n
 
 
 
=
 
 1441) 6.40 0.22–38.42
Cortisol 3 nmol/l 1.94 (
 
n
 
 
 
=
 
 1441) 1.32 0.01–8.17
% at first assessment % at second assessment Age of  onset
Cannabis use 1.2% (
 
n
 
 
 
=
 
 27) 7.2% (
 
n
 
 
 
=
 
 148) 9–12 years: 
 
n
 
 
 
=
 
 45
13–14 years: 
 
n
 
 
 
=
 
 61
 
Table 2
 
Background characteristics of  the three groups: early
starters (9–12 years old), late starters (13–14 years old), non-
users.
 
Early starters Late starters Non-users
 
Male gender 66.7% 53.8% 48.3%
DSM-orientated
scale score
Oppositional
defiant disorder
Mean (SD) 2.9 (2.5) 3.3 (2.3) 2.0 (1.9)
DSM-orientated
scale score
Conduct disorder
Mean (SD) 3.8 (4.7) 3.4 (3.2) 1.5 (2.2)
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Several authors have speculated on the significance of
hypo-arousal of  the HPA axis, which may either reflect an
under-aroused, over-regulated HPA axis or an increased
threshold for stress [42–44]. The under-aroused, over-
regulated HPA axis might be due to an increased negative
feedback inhibition which could be caused by continuous
exposure to adverse events, such as maltreatment or
post-traumatic stress disorders [45]. Of  interest for the
present study is the ‘increased threshold for stress’ theory,
which would imply that these individuals would seek
stimulation to induce a physiological response, i.e. to
arouse their HPA axis activity, in line with the sensation-
seeking theory. Stimulation may be derived from either
substance use or, for instance, externalizing behaviours,
which explains the similar findings with regard to HPA
axis activity across early onset substance users and ado-
lescents with externalizing behaviour problems.
Another finding of  the present study is the blunted
decrease during the evening for adolescents with early
and later onset of  cannabis use, which may be explained
by environmental factors common to both groups of
users, because variations in evening levels of  cortisol
were found to be due mainly to environmental influences
[20,36]. These influences may include adverse interac-
tion with peers, parent–child conflict and school prob-
lems during the day, because these factors have all been
found to predict substance use [46–48]. Most of  the early
and late onset users in our study have used cannabis only
a few times in their lives (53% of  early onset users and
65% of  late onset users have used cannabis one to three
times) and these users show even lower prevalence rates
of  actual use in the last 4 weeks (of  the early and late
onset groups, 76% and 82% did not use or used cannabis
only once, respectively). Therefore, we do not expect that
the elevated cortisol levels at 8 p.m. were caused by curr-
ent use of  cannabis in our sample.
The present study is not without limitations. First, a
general population sample is representative but is char-
acterized by low prevalence rates of  cannabis use, espe-
cially because of  our young age groups, which may have
influenced the results. However, because of  the impor-
tance of  studying correlates and predictors of  cannabis
use at an early age, our results contribute to the identifi-
cation of  adolescents at risk. Secondly, the cortisol
response to stress was not assessed, while stress reactivity
may be a key factor in the link between HPA axis activity
and early onset of  cannabis use.
In conclusion, the present study shows some evidence
for hypo-activity of  the HPA axis in adolescents with early
onset of  cannabis use, and a blunted decrease in cortisol
levels in the evening for both early and later onset users.
Further research is warranted to differentiate between
early onset and later onset users on a variety of  biological
and environmental risk factors, because early onset users
in particular form a high-risk group that needs special
attention.
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Table 3
 
Comparisons between early starters, late starters and non-users with regard to cortisol measures at awakening (cortisol 1),
30 minutes after awakening (cortisol 2) and at 8 p.m. (cortisol 3).
 
Cortisol values
 
Early starters versus non-users
 
Early starters
(n 
 
=
 
 44)
mean (SD)
Non-users
(n 
 
=
 
 1338)
mean (SD)
OR (95% CI)
 
Cortisol 1 11.11 (4.78) 11.54 (4.72) 1.01 0.95–1.08
Cortisol 2 13.50 (6.28) 15.40 (6.54) 0.95 0.91–1.00†
Cortisol 3 2.23 (1.56) 1.92 (1.30) 1.25 1.03–1.53*
Late starters versus non-users
 
Late starters
(n 
 
=
 
 59)
mean (SD)
Non-users
(n 
 
=
 
 1338)
mean (SD)
OR (95% CI)
 
Cortisol 1 11.76 (5.16) 11.54 (4.72) 0.99 0.93–1.05
Cortisol 2 16.06 (5.78) 15.40 (6.54) 1.02 0.97–1.06
Cortisol 3 2.31 (1.60) 1.92 (1.30) 1.21 1.01–1.45*
Early starters versus late starters
 
Early starters
(n 
 
=
 
 44)
mean (SD)
Late starters
(n 
 
=
 
 59)
mean (SD)
OR (95% CI)
 
Cortisol 1 11.11 (4.78) 11.76 (5.16) 1.04 0.95–1.15
Cortisol 2 13.50 (6.28) 16.06 (5.78) 0.93 0.86–0.99*
Cortisol 3 2.23 (1.56) 2.31 (1.60) 1.03 0.79–1.33
 
*
 
P
 
 
 
<
 
 0.05; †
 
P
 
 
 
<
 
 0.10; OR: odds ratio; CI: confidence interval; analyses are adjusted for gender and Tanner stage of  pubertal development.
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